Mild Clostridium difficile infection (CDI; stool frequency <four-times daily; no signs of severe colitis), clearly induced by the use of antibiotics, may be treated by stopping the inducing ...

Clostridium difficile is a spore-forming ... Once attached, the bacteria produce toxins that attack the colon lining, causing abdominal pain and diarrhea. A newly emerged hypervirulent strain of C.

Clostridium difficile infection (CDI ... with positive samples then confirmed using a toxin(s) test, to distinguish toxinogenic from nontoxinogenic CDI. Although metronidazole and vancomycin ...

Bezlotoxumab, an IgG1 monoclonal antibody targeting C. difficile toxin B, is recommended for high-risk patients to prevent further recurrences. While the addition of bezlotoxumab has shown benefit ...

Clostridium perfringens typically causes relatively mild, self-limiting, gastroenteritis. Recent data support a role for food in the epidemiology of Clostridiodes difficile infections. It is hoped ...

Considering taking supplements to treat clostridium difficile infection? Below is a list of common natural remedies used to treat or reduce the symptoms of clostridium difficile infection.

Hypoxia-inducible factor (HIF) signaling protects the intestinal mucosa from injury induced by Clostridium difficile toxins, according to the results of a study published in Gastroenterology.

Li S, Shi L, Yang Z, Zhang Y, Perez-Cordon G, Huang T, Ramsey J, Oezguen N, Savidge TC, Feng H. Critical roles of Clostridium difficile toxin B enzymatic activities in pathogenesis. Infect Immun. 2015 ...

A new UConn study reveals that tagatose, a plant-based sugar alternative, shows promise in mitigating Clostridioides ...

Our Clostridium botulinum research funded by several competitive grants from European and national sources and forms two major research lines: Fundamental research questions focus on environmental, ...

Bezlotoxumab, an IgG1 monoclonal antibody that targets C. difficile toxin B, is recommended for high-risk patients to help prevent additional recurrences. Although bezlotoxumab has proven ...